Cardiac safety profile of type II kinase inhibitors: Analysis of post-marketing reports from databases of European Medicine Agency & World Health Organization.
Atul KhuranaMandeep Kumar AroraHarikesh DubeyPublished in: Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences (2023)
Type II KI related cardiac events were serious and associated with unfavorable outcomes. A significant increase in ICSRs reporting frequency was observed with Nilotinib and Nintedanib. These results insist for a consideration of revision of cardiac safety profile of Nilotinib and Nintedanib, specifically for risks of myocardial infarction and atrial fibrillation. Additionally, the need for other ad-hoc studies is indicated.
Keyphrases
- left ventricular
- idiopathic pulmonary fibrosis
- atrial fibrillation
- heart failure
- total knee arthroplasty
- interstitial lung disease
- emergency department
- type diabetes
- adverse drug
- left atrial
- chronic myeloid leukemia
- squamous cell carcinoma
- direct oral anticoagulants
- percutaneous coronary intervention
- left atrial appendage
- mitral valve
- big data
- systemic sclerosis
- deep learning
- skeletal muscle
- case control
- climate change
- risk assessment
- rheumatoid arthritis
- drug induced
- coronary artery disease